nebivolol hydrochloride; valsartan · Abbvie · NDA 206302
Byvalson
Earliest generic entry, as listed
4 Oct 2027
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 7838552. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 7838552 | use U-185 · sets the listed date | 4 Oct 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- 24 Oct 2026Enters 12-month window basis: patent, carve-out possible · 206302-0014 Oct 2027
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 206302 · 001 · RLD · discontinued | tablet, oral | EQ 5MG BASE;80MG | 4 Oct 2027 |
Expired or delisted (1)
- US 7803838 · product · 29 Aug 2026